Ulrike Zoellner

Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia

Hagop Kantarjian, Charles L. Sawyers, Andreas Hochhaus et al. · New England Journal of Medicine · 2002 · 2K citations · Full text

Life Sciences, Hematology, Oncology +14

Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

Josep Tabernero, Federico Rojo, Emiliano Calvo et al. · Journal of Clinical Oncology · 2008 · 532 citations

Medicine, Oncology, Pharmacology +17

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

Anne O’Donnell, Sandrine Faivre, Howard A. Burris et al. · Journal of Clinical Oncology · 2008 · 479 citations

Pharmacy, Oncology, Pharmacology +17

Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study

Martin Champagne, Renaud Capdeville, Mark Krailo et al. · Blood · 2004 · 238 citations

Medicine, Hematology, Oncology +11

The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics

Ahmad Awada, Fátima Cardoso, Christel Fontaine et al. · European Journal of Cancer · 2007 · 152 citations

Medicine, Oncology, Pharmacology +14